Anti-NKG2a: Phase Ib/II started

Innate Pharma began an open-label, German Phase Ib/II trial to evaluate 4 or 10 mg/kg IPH 2201 every 2 weeks for 4 doses in 43 patients with resectable stage III-IVa squamous cell carcinoma of the ora...